Ostatné · BEAM
Beam Therapeutics Inc.
Fundamenty firmy Healthcare · Biotechnology · United States
Hodnotenie 0–10, vypočítané z údajov firmy
Analytici 13 hodnotení
silný nákup
- Najnižší cieľ
- 26,00
- Priemerný cieľ
- 52,15
- Najvyšší cieľ
- 80,00
- Potenciál
- +109,9 %
Odhad zisku na akciu (EPS)
| Obdobie | Odhad | Rozpätie | Pred rokom | Rast |
|---|---|---|---|---|
| tento štvrťrok | -1,17 | -1,28–-1,05 | -1,10 | −6,3 % |
| budúci štvrťrok | -1,19 | -1,34–-1,06 | 2,33 | −150,9 % |
| tento rok | -4,45 | -4,76–-4,24 | -0,81 | −449,8 % |
| budúci rok | -4,74 | -5,72–-3,56 | -4,45 | −6,5 % |
Odhad tržieb
| Obdobie | Odhad | Pred rokom | Rast |
|---|---|---|---|
| tento štvrťrok | 10,0 mil. | 9,7 mil. | +2,7 % |
| budúci štvrťrok | 11,6 mil. | 114,1 mil. | −89,9 % |
| tento rok | 48,6 mil. | 139,7 mil. | −65,2 % |
| budúci rok | 62,7 mil. | 48,6 mil. | +29,2 % |
Nákupy a predaje manažérov insider
| Kto | Čo | Hodnota | Dátum |
|---|---|---|---|
| Simon AmyOfficer | predaj | 429 037 | 27.07. |
| Evans John M.Chief Executive Officer | predaj | 1,7 mil. | 30.06. |
| Simon AmyOfficer | predaj | 12 954 | 30.06. |
| Evans John M.Chief Executive Officer | uplatnenie opcií | 44 781 | 30.06. |
| Fmr, L.l.c.Beneficial Owner of more than 10% of a Class of Security | predaj | 10,0 mil. | 26.06. |
| Ciaramella GiuseppePresident | uplatnenie opcií | 34 228 | 17.06. |
| Ciaramella GiuseppePresident | predaj | 290 290 | 01.04. |
| Evans John M.Chief Executive Officer | predaj | 739 317 | 01.04. |
| Bellon ChristineOfficer | predaj | 146 398 | 01.04. |
| Simon AmyOfficer | predaj | 164 686 | 01.04. |
| Cavanagh Bethany JOfficer and Treasurer | predaj | 79 688 | 01.04. |
| Ciaramella GiuseppePresident | odmena v akciách | – | 31.03. |
Kto vlastní akcie
Slávni investori: Cathie Wood · 2.3 % Stanley Druckenmiller · 0.1 % · nový
FMR, LLC12,21 %
Farallon Capital Management LLC9,91 %
ARK Investment Management, LLC9,91 %
Blackrock Inc.8,71 %
State Street Corporation5,64 %
Vanguard Portfolio Management LLC4,76 %
Vanguard Capital Management LLC4,45 %
Arch Venture Management, Llc4,40 %
O firme (popis z Yahoo Finance, anglicky)
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. The company has research collaboration agreement with Pfizer Inc., focusing on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Verve Therapeutics, Inc., for cardiovascular disease treatments; and Orbital Therapeutics to design RNA for the prevention, treatment, or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
Názor AI
Krátke zhodnotenie trendu, správ a blížiacich sa udalostí.
Technické signály
- Klesajúci trend – Kurz pod SMA50 aj SMA200
Odporúčania
K tomuto aktívu zatiaľ nemáme odporúčanie.
Predikcie
Žiadne predikcie.
Súvisiace správy
Žiadne správy so značkou BEAM.